Errata

The following additional disclosures have been received for recently published supplement to Mycoses.

‘Introduction’, *Mycoses* 2007; **50** (Suppl. 1): 1–1. O.A.C. has received research grants from Astellas, Basilea, Gilead, Merck/MSD, Pfizer, Schering-Plough and Vicuron; is a consultant to Astellas, Basilea, Gilead, Mölnlycke, Merck/MSD, Nektar, Pfizer, Schering-Plough, and Zeneus/Cephalon; and served at the speakers’ bureau of Astellas, Gilead, Merck/MSD, and Schering-Plough.

**Reference**

Original article ‘Advances in the serological diagnosis of invasive *Aspergillus* infections in patients with haematological disorders’. *Mycoses* 2007; **50** (Suppl. 1): 2–17. All authors have no conflicts of interests.

**Reference**

Original article ‘Molecular and serological diagnosis of invasive aspergillosis: new answers to old questions?’. *Mycoses* 2007; **50** (Suppl. 1): 18–23. Both authors have no conflicts of interests.

**Reference**


**Reference**

Original article ‘Treatment options in candidaemia’. *Mycoses* 2007; **50** (Suppl. 1): 44–9. O.A.C. has received research grants from Astellas, Basilea, Gilead, Merck/MSD, Pfizer, Schering-Plough and Vicuron; is a consultant to Astellas, Basilea, Gilead, Mölnlycke, Merck/MSD, Nektar, Pfizer, Schering-Plough, and Zeneus/Cephalon; and served at the speakers’ bureau of Astellas, Gilead, Merck/MSD, and Schering-Plough. M.K. is a consultant to Astellas, Pfizer, and Schering-Plough.

**Reference**

Original article ‘Zygomycosis – current epidemiological aspects’. *Mycoses* 2007; **50** (Suppl. 1): 50–5. A.G. has acted as a paid speaker to Pfizer Pharma and MSD Sharp & Dohme. O.A.C. has received research grants from Astellas, Basilea, Gilead, Merck/MSD, Pfizer, Schering-Plough and Vicuron; is a consultant to Astellas, Basilea, Gilead, Mölnlycke, Merck/MSD, Nektar, Pfizer, Schering-Plough, and Zeneus/Cephalon; and served at the speakers’ bureau of Astellas, Gilead, Merck/MSD, and Schering-Plough. J.J.V. has no conflicts of interests.

**Reference**